A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
CSL Limited
ClinicalTrials.gov Identifier:
NCT00940108
First received: July 13, 2009
Last updated: October 28, 2013
Last verified: October 2013
Results First Received: July 9, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Prevention
Condition: Influenza Caused by the Novel Influenza A (H1N1) Virus
Intervention: Biological: CSL425

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
One randomized participant withdrew consent prior to vaccine administration and was not included in the participant flow data or in any analysis population.

Reporting Groups
  Description
CSL425 (15 Mcg) Cohort A Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
CSL425 (30 Mcg) Cohort A Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
CSL425 (15 Mcg) Cohort B Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
CSL425 (30 Mcg) Cohort B Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.

Participant Flow:   Overall Study
    CSL425 (15 Mcg) Cohort A     CSL425 (30 Mcg) Cohort A     CSL425 (15 Mcg) Cohort B     CSL425 (30 Mcg) Cohort B  
STARTED     82     80     103     104  
COMPLETED     77     71     100     99  
NOT COMPLETED     5     9     3     5  
Adverse Event                 2                 4                 0                 2  
Withdrew Consent                 2                 1                 0                 1  
Dose 2 contraindicated                 1                 1                 0                 1  
Declined further vaccination                 0                 1                 3                 0  
Refused - pyrexia after Dose 1                 0                 1                 0                 0  
Viral illness after Dose 1                 0                 1                 0                 0  
Diagnosed with H1N1                 0                 0                 0                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
CSL425 (15 Mcg) Cohort A Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
CSL425 (30 Mcg) Cohort A Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
CSL425 (15 Mcg) Cohort B Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
CSL425 (30 Mcg) Cohort B Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
Total Total of all reporting groups

Baseline Measures
    CSL425 (15 Mcg) Cohort A     CSL425 (30 Mcg) Cohort A     CSL425 (15 Mcg) Cohort B     CSL425 (30 Mcg) Cohort B     Total  
Number of Participants  
[units: participants]
  82     80     103     104     369  
Age  
[units: years]
Mean ± Standard Deviation
  1.68  ± 0.67     1.73  ± 0.74     5.78  ± 1.69     5.66  ± 1.74     3.96  ± 2.42  
Gender  
[units: participants]
         
Female     41     41     53     49     184  
Male     41     39     50     55     185  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Haemagglutination Inhibition (HI) Antibody Titre Seroconversion Rate After the First Vaccination   [ Time Frame: Before and 21 days after the first vaccination ]

2.  Primary:   HI Antibody Titre Seroconversion Rate After the Second Vaccination   [ Time Frame: Before and 21 days after the second vaccination ]

3.  Primary:   Geometric Mean Fold Increase (GMFI) in the HI Antibody Titre After the First Vaccination   [ Time Frame: Before and 21 days after the first vaccination ]

4.  Primary:   GMFI in the HI Antibody Titre After the Second Vaccination   [ Time Frame: Before and 21 days after the second vaccination ]

5.  Primary:   Percentage of Participants Achieving a HI Antibody Titre of 1:40 or More After the First Vaccination   [ Time Frame: 21 days after the first vaccination ]

6.  Primary:   Percentage of Participants Achieving a HI Antibody Titre of 1:40 or More After the Second Vaccination   [ Time Frame: 21 days after the second vaccination ]
  Hide Outcome Measure 6

Measure Type Primary
Measure Title Percentage of Participants Achieving a HI Antibody Titre of 1:40 or More After the Second Vaccination
Measure Description No text entered.
Time Frame 21 days after the second vaccination  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The Evaluable Population (for the second vaccination) comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).

Reporting Groups
  Description
CSL425 (15 Mcg) Cohort A Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
CSL425 (30 Mcg) Cohort A Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
CSL425 (15 Mcg) Cohort B Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
CSL425 (30 Mcg) Cohort B Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.

Measured Values
    CSL425 (15 Mcg) Cohort A     CSL425 (30 Mcg) Cohort A     CSL425 (15 Mcg) Cohort B     CSL425 (30 Mcg) Cohort B  
Number of Participants Analyzed  
[units: participants]
  64     69     95     96  
Percentage of Participants Achieving a HI Antibody Titre of 1:40 or More After the Second Vaccination  
[units: percentage¬†of¬†participants]
Number ( 95% Confidence Interval )
  100.0  
  ( 94.4 to 100.0 )  
  100.0  
  ( 94.8 to 100.0 )  
  100.0  
  ( 96.2 to 100.0 )  
  100.0  
  ( 96.2 to 100.0 )  

No statistical analysis provided for Percentage of Participants Achieving a HI Antibody Titre of 1:40 or More After the Second Vaccination



7.  Secondary:   Frequency and Intensity of Solicited Adverse Events (AEs) After the First or Second Vaccination   [ Time Frame: During the 7 days after each vaccination ]

8.  Secondary:   Duration of Solicited AEs After the First Vaccination   [ Time Frame: During the 7 days after the first vaccination and up to Day 20 after the first vaccination if AE is ongoing at Day 7. ]

9.  Secondary:   Duration of Solicited AEs After the Second Vaccination   [ Time Frame: During the 7 days after the second vaccination and up to Day 20 after the second vaccination if AE was ongoing at Day 7. ]

10.  Secondary:   Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and New Onset of Chronic Illnesses (NOCIs)   [ Time Frame: Up to 180 days after the last vaccination ]

11.  Secondary:   Frequency and Intensity of Unsolicited Adverse Events After the First or Second Vaccination   [ Time Frame: During the 21 days after each vaccination; up to 180 days after the last vaccination for SAEs, AESIs, and NOCIs ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Clinical Trial Disclosure Manager
Organization: CSL Limited
phone: Use email contact
e-mail: csl.clinicaltrials@csl.com.au


Publications of Results:

Responsible Party: CSL Limited
ClinicalTrials.gov Identifier: NCT00940108     History of Changes
Other Study ID Numbers: CSLCT-CAL-09-60
Study First Received: July 13, 2009
Results First Received: July 9, 2013
Last Updated: October 28, 2013
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration